Formoterol

證據等級: L5

預測適應症: 6 個

Formoterol: From Established Asthma/COPD Bronchodilator Therapy to Chronic Bronchitis

One-Sentence Summary

Formoterol is a long-acting β2-adrenergic agonist (LABA) bronchodilator with an internationally established role in asthma and COPD maintenance therapy. Of the six candidate indications surfaced by TxGNN in this evidence pack, the only one that represents a genuinely new and evidence-supported signal — rather than an already-established use or a data artefact — is chronic bronchitis / COPD-related airway obstruction, backed by 28 registered clinical trials and 20 publications, including several large Phase 3 RCTs.

Note on this bundle: This evidence pack (TW-DB00983-multi) contains six TxGNN-ranked predictions for formoterol. The top-ranked one by score, “respiratory malformation,” was flagged by the evidence pipeline itself as an ontology-mapping error (the linked trials are all asthma/COPD studies unrelated to structural airway malformation). Two others (“obstructive lung disease,” “asthma”) are already-established indications, not novel repurposing candidates. Two others (“Rienhoff syndrome,” “asthma-related traits, susceptibility to”) have zero supporting evidence. Details for all six are in the addendum table at the end of this report.

Quick Overview

Item	Content
Original Indication	Not documented as structured data in this evidence pack; formoterol’s established international indications (per embedded trial/literature context) are asthma and COPD maintenance bronchodilation
Predicted New Indication	Chronic Bronchitis (COPD-spectrum airway obstruction)
TxGNN Prediction Score	99.92%
Evidence Level	L2
South Africa Market Status	Not Marketed (per this evidence pack)
Number of SAHPRA Registrations	0
Recommended Decision	Research Question

Why is This Prediction Reasonable?

Formoterol is a long-acting β2-adrenoceptor agonist (LABA). It activates β2-receptors on airway smooth muscle, raising intracellular cAMP and producing rapid, sustained bronchodilation — the same mechanism underlying its established use in asthma and COPD. This mechanism is a direct, causal fit for any disease defined primarily by reversible or partially reversible airflow obstruction.

“Bronchitis,” however, is not a single clean disease entity in this dataset — the associated trials and literature span at least three distinct conditions: (1) chronic bronchitis as a COPD phenotype, where formoterol-containing combinations (aclidinium/formoterol, budesonide/formoterol, glycopyrronium/formoterol) have large Phase 3 RCT support for airflow and symptom improvement; (2) bronchiolitis obliterans after allogeneic haematopoietic stem cell transplantation, a distinct post-transplant fibrotic small-airway disease where formoterol/budesonide combinations have been trialled with more modest, Phase 2/cohort-level evidence; and (3) acute infectious bronchitis, for which no direct evidence appears in this bundle. The prediction is mechanistically plausible for the first two entities but requires disease-entity disambiguation before it can be treated as a single “new indication.”

By contrast, formoterol’s own regulatory history in obstructive lung disease and asthma (ranks 4–5 in this bundle) is not a new prediction at all — it is formoterol’s existing, guideline-endorsed use, which only appears here as a “prediction” because this evidence pack’s original_indications field was not populated (data gap DG002 in the meta block).

Clinical Trial Evidence

Trial Number	Phase	Status	Enrollment	Key Findings
NCT01437397	Phase 3	Completed	1,692	Fixed-dose aclidinium bromide/formoterol vs. individual components and placebo, 24 weeks, moderate-to-severe stable COPD (chronic bronchitis phenotype)
NCT01462942	Phase 3	Completed	2,443	Aclidinium/formoterol fixed-dose combinations vs. components and placebo, maintenance bronchodilator treatment of COPD
NCT06571942	Phase 4	Recruiting	128	Inhaled triple therapy vs. COPD and chronic bronchitis without obstruction secondary to biomass/wood-smoke exposure
NCT01560689	Phase 2	Completed	32	Open-label inhaled budesonide/formoterol in bronchiolitis obliterans after allogeneic stem cell transplantation
NCT00403286	Phase 2	Completed	457	Dose-finding trial, fluticasone propionate/formoterol fumarate in COPD
NCT00064402	Phase 3	Completed	741	(R,R)-formoterol (arformoterol) bronchodilator effect and safety in COPD
NCT00250679	Phase 3	Completed	443	Long-term safety, arformoterol tartrate inhalation solution in COPD
NCT01049360	Phase 2	Completed	128	Aclidinium bromide/formoterol fixed-dose combinations, dose-ranging, stable moderate-to-severe COPD
NCT02526758	Phase 4	Unknown	90	Evaluation and treatment of small airway disease (obstructive bronchitis) and emphysema in COPD
NCT01361984	Phase 4	Unknown	20	Arformoterol vs. salmeterol, inspiratory capacity and HRCT comparison in COPD

28 formoterol/bronchitis trials are registered on ClinicalTrials.gov in total; the 10 above were prioritized for phase, sample size, and direct disease relevance.

Literature Evidence

PMID	Year	Type	Journal	Key Findings
27916620	2017	RCT	Chest	Glycopyrrolate/formoterol co-suspension MDI efficacy and safety in COPD (PINNACLE-1/2)
20714376	2010	Review	Int J Chron Obstruct Pulmon Dis	Clinical efficacy and safety review of nebulized formoterol in COPD
27229850	2016	Cohort	Respiratory Research	Budesonide/formoterol + montelukast + N-acetylcysteine for bronchiolitis obliterans syndrome post-HSCT
37696312	2023	Cohort	Respiratory Medicine	Inhaled tiotropium add-on to budesonide/formoterol in bronchiolitis obliterans post-HSCT
28821260	2017	Phase IIIb crossover	Respiratory Research	24-hour bronchodilation with glycopyrrolate/formoterol MDI in COPD
31920296	2019	Extension study	Int J Chron Obstruct Pulmon Dis	Long-term safety/efficacy of budesonide/glycopyrrolate/formoterol MDI in Japanese COPD patients
31015757	2019	Meta-analysis	Int J Chron Obstruct Pulmon Dis	Comparative risks of budesonide/formoterol vs. placebo/monotherapies in stable COPD
32606643	2020	Non-interventional study	Int J Chron Obstruct Pulmon Dis	Real-world effectiveness/tolerability of LABA/LAMA FDCs including aclidinium/formoterol (DETECT study)
27143870	2016	Review	Int J Chron Obstruct Pulmon Dis	Scientific rationale for LAMA+LABA dual bronchodilator therapy in COPD
41654451	2026	Pharmacovigilance study	Clinical Therapeutics	Real-world safety of budesonide/formoterol via FAERS, JADER, and CVAR databases

South Africa Market Information

This evidence pack records no SAHPRA registration entries for formoterol (0 licenses, market status “Not Marketed”). This is notable given formoterol is an internationally established respiratory medicine, and should be independently verified against SAHPRA’s current registered products list before this is treated as a true market-access gap — it may instead reflect incomplete regulatory data extraction for this evidence pack (see data gap DG001 in the meta block).

Safety Considerations

Please refer to the SAHPRA-approved Professional Information (PI) for safety information. Report adverse drug reactions to SAHPRA.

Additional context from the evidence bundle’s own analysis (not sourced from a formal safety database, verify against PI): LABA monotherapy in asthma carries a well-recognised class-level boxed-warning concern — formoterol should not be used as monotherapy in asthma and must be combined with an inhaled corticosteroid. This is flagged explicitly in the mechanistic rationale for the “asthma” prediction within this same bundle and should be treated as a guardrail item regardless of which indication is pursued.

Other Predicted Indications in This Evidence Bundle

Since this evidence pack bundles six TxGNN predictions for formoterol, the table below summarizes the other five for transparency:

Rank	Disease	TxGNN Score	Evidence Level	Recommendation	Note
1	Respiratory malformation	99.92%	L5	Hold	Flagged by the evidence pipeline as an ontology-mapping error — all 19 linked trials are asthma/COPD studies unrelated to structural airway malformation; no biological mechanism supports this link
3	Rienhoff syndrome	99.90%	L5	Hold	Rare connective-tissue disorder (TGFBR1/2 pathway); no mechanistic link to β2-agonism; zero trials, zero literature
4	Obstructive lung disease	99.90%	L1	Proceed with Guardrails	Not a novel prediction — this is formoterol’s established indication; appears here only because `original_indications` was not populated in this evidence pack
5	Asthma	99.74%	L1	Proceed with Guardrails	Same as above — established indication, not a new repurposing signal
6	Asthma-related traits, susceptibility to	99.50%	L5	Hold	A genetic susceptibility trait, not a treatable clinical disease entity; zero trials, zero literature

Conclusion and Next Steps

Decision: Research Question

Rationale: Formoterol’s bronchodilator mechanism is directly relevant to chronic bronchitis/COPD-spectrum airway obstruction, and this is supported by multiple large Phase 3 RCTs (e.g., NCT01437397, n=1,692; NCT01462942, n=2,443) — but the underlying disease-entity mapping (“bronchitis”) mixes at least two clinically distinct conditions (COPD-associated chronic bronchitis and post-transplant bronchiolitis obliterans) that need to be disambiguated before this can be treated as a single, actionable indication.

To proceed, the following is needed:

Disambiguation of “bronchitis” into its constituent clinical entities (chronic bronchitis/COPD vs. bronchiolitis obliterans) with entity-specific evidence review
SAHPRA Professional Information (PI) retrieval to confirm South African registration status, warnings, and contraindications (currently a data gap)
Confirmation of formoterol’s actual original/registered indication in South Africa, since this field was empty in the source evidence pack
Re-run of the TxGNN ontology mapping for “respiratory malformation” to correct the apparent knowledge-graph error before it is reused in future prediction cycles
Disclaimer

This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.